8-K filing — Dyne Therapeutics, Inc. (DYN)
Filed: 2026-11-05 AccNo: 0001818794-26-000013 Size: 319 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics announced its financial results for the third quarter of 2026 and provided updates on its clinical programs, including the priority review status of its BLA for z-rostudirsen.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Downgrades Dyne Therapeutics to Perform
Oppenheimer has downgraded Dyne Therapeutics from Outperform to Perform, setting a price target of $15.
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.
Dyne Therapeutics Continues To Expect Topline Data In Q1 2027 From The Achieve REC, With A Primary Endpoint Of Change From Baseline In vHOT At 6 Months, Intended To Support A Potential Submission For U.S. Accelerated Approval In Q3 2027
Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target